BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maltais F, Aumann JL, Kirsten AM, Nadreau É, Macesic H, Jin X, Hamilton A, O'Donnell DE. Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD. Eur Respir J 2019;53:1802049. [PMID: 30655277 DOI: 10.1183/13993003.02049-2018] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Blair HA. Tiotropium/Olodaterol: A Review in COPD. Drugs 2019;79:997-1008. [PMID: 31119643 DOI: 10.1007/s40265-019-01133-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
2 Berton DC, Marques RD, Palmer B, O'Donnell DE, Neder JA. Effects of lung deflation induced by tiotropium/olodaterol on the cardiocirculatory responses to exertion in COPD. Respir Med 2019;157:59-68. [PMID: 31522031 DOI: 10.1016/j.rmed.2019.09.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Beaulieu J, Jensen D, O'Donnell DE, Brouillard C, Tracey L, Vincent S, Nadreau É, Bernard E, Bernard S, Maltais F. Relieving exertional dyspnea during the 3-min constant speed shuttle test in patients with COPD with indacaterol/glycopyrronium versus tiotropium: the RED trial. Ther Adv Respir Dis 2020;14:1753466620939507. [PMID: 32663102 DOI: 10.1177/1753466620939507] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Danzo F, Radovanovic D, Gatti M, Saad M, Perotto L, Franceschi E, Santus P. A reappraisal of inspiratory capacity in chronic obstructive pulmonary disease: clinical correlates and role of long-acting muscarinic antagonists and long-acting β2 agonists. Expert Rev Respir Med 2022;:1-13. [PMID: 35722753 DOI: 10.1080/17476348.2022.2090343] [Reference Citation Analysis]
5 Román-Rodríguez M, Kocks JWH. Targeting exertional breathlessness to improve physical activity: the role of primary care. NPJ Prim Care Respir Med 2021;31:41. [PMID: 34504091 DOI: 10.1038/s41533-021-00254-8] [Reference Citation Analysis]
6 Mathioudakis AG, Vanfleteren LEGW, Lahousse L, Higham A, Allinson JP, Gotera C, Visca D, Singh D, Spanevello A. Current developments and future directions in COPD. Eur Respir Rev 2020;29:200289. [PMID: 33268439 DOI: 10.1183/16000617.0289-2020] [Reference Citation Analysis]
7 Ajimizu H, Ozasa H, Sato S, Funazo T, Sakamori Y, Nomizo T, Kuninaga K, Ogimoto T, Hosoya K, Yamazoe M, Tsuji T, Yoshida H, Itotani R, Ueno K, Kim YH, Muro S, Hirai T. Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer. Sci Rep 2021;11:23677. [PMID: 34880386 DOI: 10.1038/s41598-021-03139-5] [Reference Citation Analysis]
8 Buhl R, de la Hoz A, Xue W, Singh D, Ferguson GT. Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials. Adv Ther 2020;37:4175-89. [PMID: 32671684 DOI: 10.1007/s12325-020-01411-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
9 Milne KM, Ibrahim-Masthan M, Scheeren RE, James MD, Phillips DB, Moran-Mendoza O, Ja N, O'Donnell DE. Inspiratory neural drive and dyspnea in interstitial lung disease: Effect of inhaled fentanyl. Respir Physiol Neurobiol 2020;282:103511. [PMID: 32758677 DOI: 10.1016/j.resp.2020.103511] [Reference Citation Analysis]
10 Singh D, Donohue JF, Boucot IH, Barnes NC, Compton C, Martinez FJ. Future concepts in bronchodilation for COPD: dual- versus monotherapy. Eur Respir Rev 2021;30:210023. [PMID: 34415847 DOI: 10.1183/16000617.0023-2021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Pramanik S, Mohanto S, Manne R, Rajendran RR, Deepak A, Edapully SJ, Patil T, Katari O. Nanoparticle-Based Drug Delivery System: The Magic Bullet for the Treatment of Chronic Pulmonary Diseases. Mol Pharm 2021;18:3671-718. [PMID: 34491754 DOI: 10.1021/acs.molpharmaceut.1c00491] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Satia I, Farooqi MAM, Cusack R, Matsuoka M, Yanqing X, Kurmi O, O'Byrne PM, Killian KJ. The contribution of FEV1 and airflow limitation on the intensity of dyspnea and leg effort during exercise. Insights from a real-world cohort. Physiol Rep 2020;8:e14415. [PMID: 32323482 DOI: 10.14814/phy2.14415] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ekström M, Chang S, Johnson MJ, Fazekas B, Kochovska S, Huang C, Currow DC. Low agreement between mMRC rated by patients and clinicians: implications for practice. Eur Respir J 2019;54:1901517. [PMID: 31624113 DOI: 10.1183/13993003.01517-2019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
14 Kupaev VI, Osipov DA. Elderly age group patients with COPD continuing to smoke -a problem that cannot be ignored. Medicine in Drug Discovery 2020;6:100022. [DOI: 10.1016/j.medidd.2020.100022] [Reference Citation Analysis]
15 Lewthwaite H, Koch EM, Tracey L, Jensen D. Standardized measurement of breathlessness during exercise. Curr Opin Support Palliat Care 2019;13:152-60. [PMID: 31268873 DOI: 10.1097/SPC.0000000000000443] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
16 Maltais F, de la Hoz A, Casaburi R, O'Donnell D. Effects of Tiotropium/Olodaterol on Activity-Related Breathlessness, Exercise Endurance and Physical Activity in Patients with COPD: Narrative Review with Meta-/Pooled Analyses. Adv Ther 2021;38:835-53. [PMID: 33306188 DOI: 10.1007/s12325-020-01557-x] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Derom E, Brusselle GG, Joos GF. The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects. Ther Adv Respir Dis 2019;13:1753466619843426. [PMID: 31002020 DOI: 10.1177/1753466619843426] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Valipour A, Avdeev S, Barczyk A, Bayer V, Fridlender Z, Georgieva M, Kudela O, Medvedchikov A, Miron R, Sanzharovskaya M, Šileikienė V, Šorli J, Spielmanns M, Szalai Z. Therapeutic Success of Tiotropium/Olodaterol, Measured Using the Clinical COPD Questionnaire (CCQ), in Routine Clinical Practice: A Multinational Non-Interventional Study. Int J Chron Obstruct Pulmon Dis 2021;16:615-28. [PMID: 33731991 DOI: 10.2147/COPD.S291920] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Lewthwaite H, Koch EM, Ekström M, Hamilton A, Bourbeau J, Maltais F, Borel B, Jensen D. Predicting the rate of oxygen consumption during the 3-minute constant-rate stair stepping and shuttle tests in people with chronic obstructive pulmonary disease. J Thorac Dis 2020;12:2489-98. [PMID: 32642156 DOI: 10.21037/jtd.2020.03.13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Molina París J, Alonso Hernández PM, Díez García JA, Gonzalez Uribe-Etxebarria I, Yelo García J, Galera Llorca J, Aguilar H, Ribera X; OTIVACTO Spanish investigator's group. Assessment of physical functioning in patients with chronic obstructive pulmonary disease (COPD) requiring long-acting dual bronchodilation in routine clinical practice. Semergen 2021;47:295-304. [PMID: 33359383 DOI: 10.1016/j.semerg.2020.10.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Ekström M. Why treatment efficacy on breathlessness in laboratory but not daily life trials? The importance of standardized exertion. Curr Opin Support Palliat Care 2019;13:179-83. [PMID: 31246594 DOI: 10.1097/SPC.0000000000000444] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]